Liquidia Corporation (LQDA) SEC Filings & Earnings Calls

Settlement removes litigation overhang but introduces significant cash outflow; PH-ILD label removal may limit future revenue growth.

“Net payment of $380.7M; PH-ILD indication removed from label; no longer promoted for PH-ILD.”

Patent litigation risk for lead product YUTREPIA.

“Hatch-Waxman litigation filed by United Therapeutics.”

Regulatory and clinical development risk remains; Fast Track does not guarantee approval.

“Fast Track Designation is a regulatory milestone but does not ensure eventual FDA approval.”

Litigation risk related to YUTREPIA patents.

“Legal fees decreased $5.5 million due to ongoing YUTREPIA-related litigation.”

Patent litigation risk

“United Therapeutics has initiated multiple lawsuits against us in which it has claimed that YUTREPIA is infringing its patents” · word for word

Trade secret litigation risk

“United Therapeutics filed a complaint ... alleging that we and a former United Therapeutics employee ... conspired to misappropriate certain trade secrets of United Therapeutics”

Supply chain risk

“ICU Medical no longer manufactures or supports the CADD-MS 3 infusion pump.” · word for word

Competition risk

“We face significant competition from large pharmaceutical companies, among others, in developing and commercializing our products and product candidates” · word for word

Debt covenant risk

“Our financing facility with HCR contains operating and financial covenants that restrict our business and financing activities” · word for word

Patent litigation could force YUTREPIA market withdrawal

“United Therapeutics is seeking injunctive relief that would require YUTREPIA to be withdrawn from the market.” · word for word

Trade secret lawsuit could result in loss of intellectual property

“If United Therapeutics prevails with respect to its breach of contract claims, we could be required to assign an interest in certain of our intellectual property, including our '494 patent, to United Therapeutics.” · word for word

Treprostinil Injection sales constrained by pump unavailability

“ICU Medical no longer manufactures or supports the CADD-MS 3 infusion pump... the number of patients that can receive subcutaneous administration of Treprostinil Injection will continue to be constrained.” · word for word

Dependence on single supplier for key components

“We depend on third parties for clinical and commercial supplies, including single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the drug product and device for L606.” · word for word

HCR debt covenant restricts operations and requires $15M minimum cash

“we are required to maintain at all times a minimum cash balance of $15.0 million.” · word for word

Litigation risk: ongoing YUTREPIA-related litigation could impact future sales or margins.

“These increases were partially offset by a $3.7 million decrease in legal fees related to our ongoing YUTREPIA-related litigation.” · word for word

Commercial execution risk: sustained adoption of YUTREPIA depends on prescriber uptake and competition.

“Increased total number of prescribers to more than 980 since launch.” · word for word

Competitive risk from other treprostinil formulations

“The prostacyclin category across PAH and PH-ILD represents more than $4.5 billion in branded product sales today, with treprostinil formulations accounting for nearly $2.9 billion of that total.” · word for word

Dependence on YUTREPIA for revenue

“YUTREPIA is the sole commercial product; L606 is still in pivotal Phase 3.”

Ongoing YUTREPIA litigation could impact future revenue or market exclusivity.

“Legal fees increased $5.3 million related to ongoing YUTREPIA-related litigation.”

Heavy reliance on YUTREPIA for revenue; pipeline L606 still in development.

“Product sales entirely from YUTREPIA; L606 in pivotal trials.”

Patent litigation could remove YUTREPIA from market

“United Therapeutics is seeking injunctive relief that would require YUTREPIA to be withdrawn from the market.” · word for word

Single-product dependency

“We are primarily dependent on the success of YUTREPIA, for which we recently received FDA approval” · word for word

Need for additional capital

“In the event revenues from YUTREPIA are insufficient to support our future capital needs, we expect that we would need further financing” · word for word

Dependence on single product YUTREPIA for revenue; pipeline still in development.

“Revenue entirely from YUTREPIA; L606 and other pipeline candidates are investigational.”

Competitive landscape in PAH/PH-ILD with existing therapies (Tyvaso, Uptravi, Winrevair).

“Mentions of competitor products Tyvaso, Uptravi, Winrevair in pipeline studies.”

Patent litigation could force product withdrawal

“United Therapeutics is seeking injunctive relief that would require YUTREPIA to be withdrawn from the market.” · word for word

History of losses and uncertain profitability

“We have incurred net losses of $83.5 million during the nine months ended September 30, 2025, and $128.3 million and $78.5 million during the years ended December 31, 2024 and 2023, respectively.” · word for word

Single supplier dependency

“We depend on third parties for clinical and commercial supplies, including single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the drug product and device for L606.” · word for word

Ongoing litigation related to YUTREPIA; legal fees increased.

“a $1.3 million increase in legal fees related to our ongoing YUTREPIA-related litigation” · word for word

Development and regulatory risks for L606; reliance on Vectura for device supply.

“Milestone payments tied to development and sales; royalty rates mid-single digits.”